title: Editorial commentary: Risks and benefits of tenofovir in the context of kidney dysfunction in sub-Saharan Africa.
authors.affiliation: Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: Michelle M
authors.initials: MM
authors.lastname: Estrella
authors.forename: Mohammed R
authors.initials: MR
authors.lastname: Moosa
authors.forename: Jean B
authors.initials: JB
authors.lastname: Nachega
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000503:physiopathology*; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000139:chemically induced*
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D000225:Adenine
keywords: HIV; kidney disease; sub-Saharan Africa; tenofovir